Navigation Links
BioMS Medical announces first quarter 2008 results
Date:5/15/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, May 15 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the first quarter ended March 31, 2008. BioMS, in partnership with Eli Lilly and Company, is developing dirucotide (also known as MBP8298), a synthetic peptide drug for the treatment of MS undergoing pivotal trials in Canada, Europe and the US.

"During the quarter, we completed our landmark partnership deal with Eli Lilly and Company," said Kevin Giese, President and CEO of BioMS Medical. "We now look forward to multiple clinical milestones for dirucotide (MBP8298) over the next 24 months. In the near-term, the Data Safety Monitoring Board for our MAESTRO-01 pivotal trial will review data from the first 200 patients in the trial and recommend whether the trial should continue. A positive outcome from this review, anticipated in the third quarter of 2008, is expected to trigger a milestone payment from our new partner."

Currently, BioMS is conducting three clinical trials and one open-label follow-on trial for dirucotide (MBP8298):

- MAESTRO-01: A pivotal phase II/III trial in Canada and Western Europe

evaluating dirucotide (MBP8298) for the treatment of secondary

progressive MS (SPMS). On January 22, 2007, BioMS announced that the

trial had completed full recruitment of 611 patients at 47 trial

sites in 10 countries. Patients are administered either dirucotide

(MBP8298) or placebo every six months for a period of two years. To

date, there have been eight positive safety reviews from the

Data Safety Monitoring Board (DSMB).

- MAESTRO-02: An open-label follow-on study to the MAESTRO-01 pivotal

trial. Eligible patients who have successfully completed the blinded,

placebo controlled MAESTRO-
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... ... ... global failure analysis market is expected to reach $7,147.0 million by 2020, at a ... at the highest CAGR of 8.46%; its growth is expected to be driven by ... for root cause analysis of failure. The market based on the geographic regions has ...
(Date:7/3/2015)... 3, 2015 Forskere ... 2015 på  http://www.openinnovationinscience.at om efteruddannelsesprogrammet "Lab ... sted i Wien .  ... internationale forskere og videnskabsmænd foretaget af Ludwig ... udfordringer for sundhedsvidenskaben manglen på incitamenter til ...
(Date:7/2/2015)... , July 2, 2015 Amici ... Bio-tech procurement company Amici Procurement has chosen Microsoft Cloud ... it move to Office 365.      (Logo: ... small to medium-sized companies in the bio-tech sector with ... of the purchasing cycle to help them obtain best ...
(Date:7/1/2015)... and PARIS , ... AgBiome, and Genective, key developer of biotech crops, ... discovery of new generations of insect control traits. ... control to counter the realities of advancing insect ... aligning AgBiome,s unique insect control technology with Genective,s ...
Breaking Biology Technology:Failure Analysis Market to Grow at 7.52% CAGR to 2020 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 4Failure Analysis Market to Grow at 7.52% CAGR to 2020 5Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3Biotech Procurement Company Moves to Office 365 with iomart 2AgBiome and Genective collaborate to create novel insect-resistant crops 2
... specialist and a healthcare economist both say that the ... drug to market does not hold up to close ... (GEN). The researchers emphasize that available cost data cannot ... internal and external sources of variability, according to the ...
... KALAMAZOO, Mich., July 6, 2011 Metabolic Solutions Development ... novel molecular targets to treat metabolic diseases, announced today ... Alzheimer,s Drug Discovery Foundation (ADDF) to conduct a pilot ... the treatment of metabolic diseases associated with altered mitochondrial ...
... Inc., a privately held company developing and commercializing novel ... for new and existing therapeutics, announced today that effective ... been elected as chairman for the company,s board of ... pathologist with more than 20 years experience in the ...
Cached Biology Technology:GEN point of view article questions reported costs of drug R&D 2Metabolic Solutions Development Company Receives $773,000 From the Alzheimer's Drug Discovery Foundation to Fund Phase 2a Trial 2Metabolic Solutions Development Company Receives $773,000 From the Alzheimer's Drug Discovery Foundation to Fund Phase 2a Trial 3Saladax Biomedical, Inc. Announces Appointment of Gregory C. Critchfield, M.D., M.S. as Chairman of the Company's Board of Directors 2Saladax Biomedical, Inc. Announces Appointment of Gregory C. Critchfield, M.D., M.S. as Chairman of the Company's Board of Directors 3
(Date:6/17/2015)... , June 17, 2015 QIAGEN ... launched new Investigator ® STR assay kits for analysis ... United States . The new genetic fingerprint kits provide ... (short tandem repeats or STRs) for DNA matching. They incorporate ... of DNA in each sample, a novel QIAGEN technology that ...
(Date:6/16/2015)... , June 16, 2015  With the increasing ... security remains a top concern. The recent compromise of ... the need for strong authentication within government agencies. ... a biometric one-time password (OTP) authenticator, has been submitted ... (FIPS) 140-2 Level 3 validation for tamper proofing. ...
(Date:6/15/2015)... -- A new report [ 1 ... US consumers using mobile banking applications want their mobile devices ... voiceprint, instead of having to prove who they are with ... Identity   -   The Fusion of Financial Services, Mobile ... primary channel used by Gen X and Gen Y to ...
Breaking Biology News(10 mins):QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4
... University of Kansas researchers have found that the infants ... fatty acid DHA during pregnancy weighed more at birth and ... born before 34 weeks gestation than infants of mothers who ... for using the dietary supplement during pregnancy. Susan CarlsonThe ...
... what may be a major factor behind the increased ... in vitro fertilization (IVF). Two papers published in ... hypothesis that extremely high estrogen levels at the time ... be born small for their gestational age and the ...
... of Nottingham has been used in a breakthrough study ... fully functioning fetal heart. The abdominal fetal ECG ... of Electrical and Electronic Engineering and on commercial sale ... company Monica Healthcare Ltd, has been used to observe ...
Cached Biology News:Prenatal DHA reduces early preterm birth, low birth weight 2Extremely high estrogen levels may underlie complications of single-birth IVF pregnancies 2Extremely high estrogen levels may underlie complications of single-birth IVF pregnancies 3Nottingham technology in heart development breakthrough 2Nottingham technology in heart development breakthrough 3Nottingham technology in heart development breakthrough 4